Der Internist

, Volume 58, Issue 5, pp 469–479 | Cite as

Das hepatozelluläre Karzinom

  • C. Czauderna
  • J. U. Marquardt
  • P. R. Galle
  • M. A. Wörns
CME
  • 695 Downloads

Zusammenfassung

Das hepatozelluläre Karzinom (HCC) ist ein hochmaligner Tumor, der bei Patienten mit Leberzirrhose die häufigste Todesursache darstellt. Die Leberzirrhose wiederum ist der wichtigste Risikofaktor für die HCC-Entstehung. Insbesondere weil die Häufigkeit der nichtalkoholischen Steatohepatitis zunimmt, ist auch in der westlichen Welt mit einem weiteren Anstieg der HCC-Inzidenz zu rechnen. Identifikation und Überwachung von Hochrisikopatienten sind entscheidend, da nur für das Frühstadium der Erkrankung potenziell kurative Therapieansätze bestehen. Angesichts der häufig zugrunde liegenden Leberzirrhose sind Therapiestrategien v. a. im fortgeschrittenen Stadium begrenzt und erfordern eine enge interdisziplinäre Zusammenarbeit und multimodale Behandlungskonzepte. Die morphologische und molekulargenetische Heterogenität des HCC ist die größte Herausforderung für neue Therapieansätze. Soll die Prognose verbessert werden, erscheint daher eine individualisierte Präzisionsmedizin unerlässlich.

Schlüsselwörter

Leberzirrhose Tumorfrüherkennung Personalisierte Medizin Chemoembolisation Lebertransplantation 

Hepatocellular carcinoma

Abstract

Hepatocellular carcinoma (HCC) is a highly malignant tumor and is the most common cause of death in patients with underlying liver cirrhosis. The main risk factor for development of HCC is liver cirrhosis. Because of the increasing frequency of nonalcoholic steatohepatitis, the incidence of HCC is also expected to considerably rise in Western countries in upcoming years. Identification and surveillance of patients at risk is crucial because curative treatment approaches can only be applied at early stages of the disease. Due to underlying liver cirrhosis, therapeutic strategies are limited and require intense interdisciplinary cooperation and multimodal approaches. However, a strong morphological and genetic heterogeneity of HCC remains a major challenge for development of new treatment modalities and demands personalized precision medicine approaches in order to improve patient outcome.

Keywords

Liver cirrhosis Early detection of cancer Personalized medicine Chemoembolization, therapeutic Liver transplantation 

Notes

Einhaltung ethischer Richtlinien

Interessenkonflikt

C. Czauderna, J.U. Marquardt, P.R. Galle und M.A. Wörns geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Literatur

  1. 1.
    Global Burden of Disease Cancer Collaboration, Global Burden of Disease Cancer, C., et al (2016) Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: A systematic analysis for the global burden of disease study. JAMA Oncol. doi: 10.1001/jamaoncol.2016.5688 Google Scholar
  2. 2.
    Njei B, Rotman Y, Ditah I, Lim JK (2015) Emerging trends in hepatocellular carcinoma incidence and mortality. Hepatology 61:191–199CrossRefPubMedGoogle Scholar
  3. 3.
    European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer (2012) EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 56(4):908–943CrossRefGoogle Scholar
  4. 4.
    Kao JH (2015) Hepatitis B vaccination and prevention of hepatocellular carcinoma. Best Pract Res Clin Gastroenterol 29(6):907–917CrossRefPubMedGoogle Scholar
  5. 5.
    Turati F et al (2013) Metabolic syndrome and hepatocellular carcinoma risk. Br J Cancer 108(1):222–228CrossRefPubMedGoogle Scholar
  6. 6.
    Greten TF et al (2013) Diagnosis of and therapy for hepatocellular carcinoma. Z Gastroenterol 51(11):1269–1326CrossRefPubMedGoogle Scholar
  7. 7.
    Bruix J, Sherman M, American Association for the Study of Liver Diseases (2011) Management of hepatocellular carcinoma: an update. Hepatology 53(3):1020–1022CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Vilgrain V (2010) Advancement in HCC imaging: diagnosis, staging and treatment efficacy assessments: hepatocellular carcinoma: imaging in assessing treatment efficacy. J Hepatobiliary Pancreat Sci 17(4):374–379. doi: 10.1007/s00534-009-0230-3 CrossRefPubMedGoogle Scholar
  9. 9.
    Llovet JM, Bru C, Bruix J (1999) Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19(3):329–338CrossRefPubMedGoogle Scholar
  10. 10.
    Park JW et al (2015) Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int 35(9):2155–2166CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Imamura H et al (2003) Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 38(2):200–207CrossRefPubMedGoogle Scholar
  12. 12.
    Mazzaferro V et al (1996) Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334(11):693–699CrossRefPubMedGoogle Scholar
  13. 13.
    Yao FY et al (2008) Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology 48(3):819–827CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Forner A, Llovet JM, Bruix J (2012) Hepatocellular carcinoma. Lancet 379(9822):1245–1255CrossRefPubMedGoogle Scholar
  15. 15.
    Bruix J et al (2015) Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol 16(13):1344–1354CrossRefPubMedGoogle Scholar
  16. 16.
    Geissler EK et al (2016) Sirolimus use in liver transplant recipients with hepatocellular carcinoma: a randomized, multicenter, open-label phase 3 trial. Transplantation 100(1):116–125CrossRefPubMedGoogle Scholar
  17. 17.
    Llovet JM, Bruix J (2003) Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37(2):429–442CrossRefPubMedGoogle Scholar
  18. 18.
    Lencioni R, Llovet JM (2010) Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30(1):52–60CrossRefPubMedGoogle Scholar
  19. 19.
    Forner A, Gilabert M, Bruix J, Raoul JL (2014) Treatment of intermediate-stage hepatocellular carcinoma. Nat Rev Clin Oncol 11(9):525–535. doi: 10.1038/nrclinonc.2014.122 CrossRefPubMedGoogle Scholar
  20. 20.
    Salem R, Lewandowski RJ (2013) Chemoembolization and radioembolization for hepatocellular carcinoma. Clin Gastroenterol Hepatol 11(6):604–611 (quiz e43-4.)CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Llovet JM et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359(4):378–390CrossRefPubMedGoogle Scholar
  22. 22.
    Wörns MA, Galle PR (2010) Novel inhibitors in development for hepatocellular carcinoma. Expert Opin Investig Drugs 19:615–629CrossRefPubMedGoogle Scholar
  23. 23.
    Wörns MA, Klöckner R, Weinmann A, Galle PR (2013) Therapie des hepatozellulären Karzinoms. Internist 55:23–30. doi: 10.1007/s00108-013-3318-4 CrossRefGoogle Scholar
  24. 24.
    Worns MA, Galle PR (2014) HCC therapies – lessons learned. Nat Rev Gastroenterol Hepatol 11(7):447–452CrossRefPubMedGoogle Scholar
  25. 25.
    Bruix J et al (2016) Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 389:56. doi: 10.1016/s0140-6736(16)32453-9 CrossRefPubMedGoogle Scholar
  26. 26.
    Sangro B, Gomez-Martin C, de la Mata M, Iñarrairaegui M, Garralda E, Barrera P, Riezu-Boj JI, Larrea E, Alfaro C, Sarobe P, Lasarte JJ, Pérez-Gracia JL, Melero I, Prieto J (2013) A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol 59(1):81–88. doi: 10.1016/j.jhep.2013.02.022 CrossRefPubMedGoogle Scholar
  27. 27.
    El-Khoueiry AB, Melero I, Crocenzi TS et al (2015) Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): Ca209-040. J Clin Oncol 33(suppl):abstr LBA101CrossRefGoogle Scholar
  28. 28.
    Llovet JM, Villanueva A, Lachenmayer A, Finn RS (2015) Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nat Rev Clin Oncol 12(7):408–424. doi: 10.1038/nrclinonc.2015.103 CrossRefPubMedGoogle Scholar
  29. 29.
    Marquardt JU, Andersen JB (2015) Liver cancer oncogenomics: opportunities and dilemmas for clinical applications. Hepat Oncol 2(1):79–93CrossRefPubMedGoogle Scholar
  30. 30.
    Santoro A, Rimassa L, Borbath I et al (2013) Tivantinib for second-line treatment of advanced hepa- tocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol 14:55–63CrossRefPubMedGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH 2017

Authors and Affiliations

  • C. Czauderna
    • 1
  • J. U. Marquardt
    • 1
  • P. R. Galle
    • 1
  • M. A. Wörns
    • 1
  1. 1.I. Medizinische Klinik und Poliklinik/Cirrhose Centrum Mainz (CCM)Universitätsmedizin der Johannes Gutenberg-Universität MainzMainzDeutschland

Personalised recommendations